Robin Kate Kelley

Robin Kate Kelley at UCSF is a specialist in hepatobiliary malignancies with expertise in biliary tract cancer immunotherapy and combination strategies. Her research has evaluated nivolumab, pembrolizumab, and other immune checkpoint inhibitors in biliary tract cancer, contributing to understanding which patients benefit from immunotherapy. She has led early-phase clinical trials combining immunotherapy with targeted agents and chemotherapy in BTC. Her translational work on biomarkers of immunotherapy response in BTC including TMB, PDL1, and gut microbiome has contributed to patient selection.